Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

Soluble Guanylate Cyclase Stimulator

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Patients With Heart Failure ◽

Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2020.09.030 ◽

2020 ◽

Vol 26 (10) ◽

pp. S8

Author(s):

James E. Udelson ◽

Gregory D. Lewis ◽

Sanjiv J. Shah ◽

Michael R. Zile ◽

Margaret M. Redfield ◽

...

Keyword(s):

Heart Failure ◽

Soluble Guanylate Cyclase ◽

Soluble Guanylate Cyclase Stimulator

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Patients With Heart Failure ◽

A multinational, randomized, double-blind, placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime in Type 2 or non-ambulatory Type 3 spinal muscular atrophy

Neuromuscular Disorders ◽

10.1016/s0960-8966(17)30304-8 ◽

2017 ◽

Vol 27 ◽

pp. S29

Author(s):

J. Buchbjerg ◽

E. Bertini ◽

E. Dessaud ◽

E. Mercuri ◽

F. Muntoni ◽

...

Keyword(s):

Spinal Muscular Atrophy ◽

Muscular Atrophy ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Type 3

T136. Safety and Efficacy of Intravenous Ganaxolone in Severe Postpartum Depression: Results From a Double-Blind, Placebo-Controlled Phase 2 Study

Biological Psychiatry ◽

10.1016/j.biopsych.2019.03.459 ◽

2019 ◽

Vol 85 (10) ◽

pp. S181-S182

Author(s):

Rolando Gutierrez-Esteinou ◽

Bassem Maximos ◽

Robert Riesenberg ◽

Kimball A. Johnson ◽

Alex Aimetti ◽

...

Keyword(s):

Postpartum Depression ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Soluble Guanylate Cyclase Stimulator

1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease

Diabetes ◽

10.2337/db20-1073-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1073-P

Author(s):

JOHN P. HANRAHAN ◽

IAN DE BOER ◽

GEORGE BAKRIS ◽

PHEBE WILSON ◽

JAMES D. WAKEFIELD ◽

...

Keyword(s):

Kidney Disease ◽

Guanylate Cyclase ◽

Diabetic Kidney Disease ◽

Soluble Guanylate Cyclase ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Diabetic Kidney ◽

Double Blind Placebo ◽

(409) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy

Journal of Pain ◽

10.1016/j.jpain.2019.02.094 ◽

2019 ◽

Vol 20 (4) ◽

pp. S73 ◽

Cited By ~ 1

Author(s):

S. Torri ◽

S. Sainati ◽

M. Burak ◽

J. Hamilton ◽

N. Katz ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Diabetic Peripheral Neuropathy ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Painful Diabetic Peripheral Neuropathy ◽

SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON’S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY

10.1136/annrheumdis-2019-eular.2672 ◽

2019 ◽

Cited By ~ 1

Author(s):

Mark C. Genovese ◽

Alberto Spindler ◽

Akira Sagawa ◽

Won Park ◽

Anna Dudek ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Phase 2 ◽

Double Blind ◽

Bruton's Tyrosine Kinase ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE‐TPA): A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study

Annals of Neurology ◽

10.1002/ana.25644 ◽

2019 ◽

Vol 87 (2) ◽

pp. 233-245 ◽

Cited By ~ 4

Author(s):

Jong S. Kim ◽

Kyung Bok Lee ◽

Jong‐Ho Park ◽

Sang Min Sung ◽

Kyungmi Oh ◽

...

Keyword(s):

Ischemic Stroke ◽

Acute Ischemic Stroke ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction

JACC Heart Failure ◽

10.1016/j.jchf.2013.12.002 ◽

2014 ◽

Vol 2 (2) ◽

pp. 123-130 ◽

Cited By ~ 51

Author(s):

Michael R. Zile ◽

Robert C. Bourge ◽

Margaret M. Redfield ◽

Duo Zhou ◽

Catalin F. Baicu ◽

...

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Exercise Tolerance ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Patients With Heart Failure

Faculty Opinions recommendation of Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718312018.793492379 ◽

2014 ◽

Author(s):

Michael Frenneaux ◽

Satnam Singh

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Exercise Tolerance ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Patients With Heart Failure

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Randomised Controlled